On April 2, 2014 Bayer HealthCare reported that the company has begun to enroll patients in a new Phase III trial with radium-223 dichloride (radium-223, Xofigo) (Press release Bayer, APR 1, 2014, View Source;L=1&tx_news_pi1%5Bnews%5D=1672 [SID:1234500360]). The study evaluates radium-223 in combination with abiraterone acetate and prednisone/prednisolone for the treatment of asymptomatic or mildly symptomatic chemotherapy-naïve patients with bone predominant metastatic castration-resistant prostate cancer (CRPC). The trial is designed to determine the effects of this combination treatment on symptomatic skeletal event-free survival (SSE-FS).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!